Literature DB >> 19588486

Rectal cancer survival in the Nordic countries and Scotland.

Joakim Folkesson1, Gerda Engholm, Eva Ehrnrooth, Anne-Mette Kejs, Lars Påhlman, Henrik Harling, Arne Wibe, Maria Gaard, Jónsson Thornorvaldur, Laufey Tryggvadottir, David H Brewster, Timo Hakulinen, Hans H Storm.   

Abstract

The aim of this study was to present detailed population-based survival estimates for patients with a rectal adenocarcinoma, using cancer register data supplemented with clinical data. Based on cancer register data, differences in rectal cancer survival have been reported between countries in Europe. Variation in the distribution of stage at diagnosis, initial therapy including surgical technique, and comorbidity are possible explanatory factors. Adenocarcinomas in the rectum, diagnosed in 1997 and identified in the national cancer registries in the Nordic countries and Scotland were included. Age standardized 5-year relative survival and multiplicative regression models for the relative excess mortality were calculated. 3888 patients were included in the survival study. Men in Denmark, Finland and Iceland had lower 5-year relative survival and poorer stage distribution compared to Norway, Sweden and Scotland. Danish men had the highest rate of excess deaths in the first six months after diagnosis. Stage adjusted, the elevated relative excess mortality decreased and after six months the excess mortality rates were the same in all countries. The poor 5-year relative survival in Danish men was mainly due to a high excess rate of death during the first six months after diagnosis. The low survival in Finland and Iceland was not in accordance with other periods. For both countries this may be explained by random variation due to small numbers. The study emphasizes the need for high quality and detailed data in order to understand international survival differences, and cautions comparisons between large national samples and those of smaller areas.

Entities:  

Mesh:

Year:  2009        PMID: 19588486     DOI: 10.1002/ijc.24562

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).

Authors:  Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman
Journal:  Lancet       Date:  2014-11-26       Impact factor: 79.321

Review 2.  [Intra-operative local tumor cell dissemination in rectal carcinoma surgery: effect of operation principles and neoadjuvant therapy].

Authors:  S Merkel; W Hohenberger; P Hermanek
Journal:  Chirurg       Date:  2010-08       Impact factor: 0.955

3.  Survival of patients with kidney cancer in central and northern Denmark, 1998-2009.

Authors:  Tau Pelant; Erik Højkjær Larsen; Lars Lund; Michael Borre; Rune Erichsen; Mette Nørgaard; Jacob Bonde Jacobsen
Journal:  Clin Epidemiol       Date:  2011-07-21       Impact factor: 4.790

4.  Early mortality from colorectal cancer in England: a retrospective observational study of the factors associated with death in the first year after diagnosis.

Authors:  A Downing; A Aravani; U Macleod; S Oliver; P J Finan; J D Thomas; P Quirke; J R Wilkinson; E J A Morris
Journal:  Br J Cancer       Date:  2013-01-03       Impact factor: 7.640

5.  Management of colorectal cancer explains differences in 1-year relative survival between France and England for patients diagnosed 1997-2004.

Authors:  O Dejardin; B Rachet; E Morris; V Bouvier; V Jooste; R Haynes; E G Coombes; D Forman; A P Jones; A M Bouvier; G Launoy
Journal:  Br J Cancer       Date:  2013-02-07       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.